Bluevac-3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3 for use in sheep and cattle.
Ceva says it reduces viraemia, prevents mortality and reduces the clinical signs of BTV-3 in sheep and reduces viraemia in cattle.
In sheep, Bluevac-3 can be administered from two months of age and two doses of 2ml should be administered subcutaneously three weeks apart.
In cattle, the vaccine can be administered from two months of age and two doses of 4ml should be administered three weeks apart.
Onset of immunity occurs 21 days/three weeks after completion of primary vaccination in cattle and sheep.
The vaccine can be used in pregnancy in cows and ewes.
No negative impact on milk-yield after using the vaccine in lactating ewes and cows is expected.
Ceva developed the new vaccine in partnership with vaccine manufacturer CZV Vaccines and launched it in Europe early in the summer, to mitigate the impact of the disease already experienced in the Netherlands, Belgium, and Germany.
Craig Wright, ruminant business unit director at Ceva Animal Health, said: “In co-operation with our partner, CZV Vaccines, we have worked tirelessly to bring Bluevac-3 to the UK to help fight bluetongue which has the potential to cause severe financial loss to farmers.
"The availability of an effective vaccine is an essential tool to help suppress future outbreaks by reducing viraemia, preventing mortality and reducing the clinical signs of BTV-3.”
Licences to allow the use of the new vaccine will either be geographically targeted general licences, initially in high risk counties as part of a phased approach, or specific licences which can be applied for through APHA.
General licencing will be subject to risk assessment.
https://www.gov.uk/government/publications/summary-of-product-characteristics-for-bluevac-3-btv-3-vaccine-in-the-uk.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.